Letters to the editor for April 13, 2021 newsadvance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsadvance.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 12, 2021
SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This is the third approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after fail
The new investment that the company is making this year will focus on building components for smart vehicles, including software platforms for self-driving cars, CGTN reported on Tuesday, citing Huawei s Rotating Chairman Eric Xu.Spea